Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune BiologySAN ANTONIO, Jan. 12, 2026 /PRNewswire/ -- ...
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 followin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback